These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21303921)

  • 1. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs.
    Obaidat A; Weiss J; Wahlgren B; Manam RR; Macherla VR; McArthur K; Chao TH; Palladino MA; Lloyd GK; Potts BC; Enna SJ; Neuteboom ST; Hagenbuch B
    J Pharmacol Exp Ther; 2011 May; 337(2):479-86. PubMed ID: 21303921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marizomib, a potent second generation proteasome inhibitor from natural origin.
    Ma L; Diao A
    Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells.
    Piskorz WM; Krętowski R; Cechowska-Pasko M
    Mar Drugs; 2024 Jul; 22(7):. PubMed ID: 39057424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.
    Miller CP; Manton CA; Hale R; Debose L; Macherla VR; Potts BC; Palladino MA; Chandra J
    Chem Biol Interact; 2011 Oct; 194(1):58-68. PubMed ID: 21864512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
    Macherla VR; Mitchell SS; Manam RR; Reed KA; Chao TH; Nicholson B; Deyanat-Yazdi G; Mai B; Jensen PR; Fenical WF; Neuteboom ST; Lam KS; Palladino MA; Potts BC
    J Med Chem; 2005 Jun; 48(11):3684-7. PubMed ID: 15916417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
    Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
    Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
    Potts BC; Lam KS
    Mar Drugs; 2010 Mar; 8(4):835-80. PubMed ID: 20479958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
    Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
    Ruiz S; Krupnik Y; Keating M; Chandra J; Palladino M; McConkey D
    Mol Cancer Ther; 2006 Jul; 5(7):1836-43. PubMed ID: 16891470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
    Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B
    Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
    Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
    Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.